Stephen K Tahir
Overview
Explore the profile of Stephen K Tahir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
5301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang H, Xue J, Hessler P, Tahir S, Chen J, Jin S, et al.
Mol Cancer
. 2015 Jul;
14:126.
PMID: 26134786
Background: Defects in programmed cell death, or apoptosis, are a hallmark of cancer. The anti-apoptotic B-cell lymphoma 2 (BCL-2) family proteins, including BCL-2, BCL-X(L), and MCL-1 have been characterized as...
12.
Bruncko M, Wang L, Sheppard G, Phillips D, Tahir S, Xue J, et al.
J Med Chem
. 2015 May;
58(9):4089.
PMID: 25933255
No abstract available.
13.
Leverson J, Phillips D, Mitten M, Boghaert E, Diaz D, Tahir S, et al.
Sci Transl Med
. 2015 Mar;
7(279):279ra40.
PMID: 25787766
The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its efficacy in these settings is limited by thrombocytopenia caused by...
14.
Bruncko M, Wang L, Sheppard G, Phillips D, Tahir S, Xue J, et al.
J Med Chem
. 2015 Feb;
58(5):2180-94.
PMID: 25679114
Myeloid cell leukemia 1 (MCL-1) is a BCL-2 family protein that has been implicated in the progression and survival of multiple tumor types. Herein we report a series of MCL-1...
15.
Tao Z, Hasvold L, Wang L, Wang X, Petros A, Park C, et al.
ACS Med Chem Lett
. 2014 Oct;
5(10):1088-93.
PMID: 25313317
A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines...
16.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J, et al.
Nat Med
. 2013 Jan;
19(2):202-8.
PMID: 23291630
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter...
17.
Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten M, et al.
Mol Cancer Ther
. 2011 Sep;
10(12):2340-9.
PMID: 21914853
The ability of a cancer cell to avoid apoptosis is crucial to tumorigenesis and can also contribute to chemoresistance. The Bcl-2 family of prosurvival proteins (Bcl-2, Bcl-X(L), Bcl-w, Mcl-1, and...
18.
Bruncko M, Tahir S, Song X, Chen J, Ding H, Huth J, et al.
Bioorg Med Chem Lett
. 2010 Nov;
20(24):7503-6.
PMID: 21106457
We describe the development of a novel series of N-aryl-benzimidazolone HSP90 inhibitors (9) targeting the N-terminal ATP-ase site. SAR development was influenced by structure-based design based around X-ray structures of...
19.
Tahir S, Wass J, Joseph M, Devanarayan V, Hessler P, Zhang H, et al.
Mol Cancer Ther
. 2010 Feb;
9(3):545-57.
PMID: 20179162
ABT-263 inhibits the antiapoptotic proteins Bcl-2, Bcl-x(L), and Bcl-w and has single-agent efficacy in numerous small cell lung carcinoma (SCLC) and leukemia/lymphoma cell lines in vitro and in vivo. It...
20.
Ackler S, Mitten M, Foster K, Oleksijew A, Refici M, Tahir S, et al.
Cancer Chemother Pharmacol
. 2010 Jan;
66(5):869-80.
PMID: 20099064
Purpose: This study was designed to test the ability of the Bcl-2 family inhibitor ABT-263 to potentiate commonly used chemotherapeutic agents and regimens in hematologic tumor models. Methods: Models of...